Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISHL12 | The importance of cardio-oncology in the treatment of patients with hematological malignancies

Jenica Upshaw • 19 Oct 2022
ISHL12 ISHL12 2022
General Hodgkin Lymphoma Lymphoma

In this video, Jenica Upshaw, MD, Tufts University, Boston, MA, briefly discusses the role of cardio-oncology in the treatment of patients with hematological malignancies including Hodgkin lymphoma (HL), and explains the importance of optimizing cardiovascular health to improve patient outcomes. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jenica Upshaw

2:22
The importance of assessing cardiac risk in patients undergoing treatment for HL
Jenica Upshaw • 19 Sep 2022
3:07
The effect of heart failure on the management and outcomes of older patients with Hodgkin lymphoma
Jenica Upshaw • 19 Oct 2022

Related Videos

3:12
Addressing cardiotoxicity following CAR-T therapy and improving clinical practice
Arjun Ghosh • 25 Apr 2024
4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals